Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 3/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310101 | 1.00 | BLM (0.50) | BLMTDP1ADRB2NFKB1KDM4E | |
| SCHEMBL12185812 | 0.86 | ADRB2 (0.54) | BLMTDP1ADRB2NFKB1KDM4E | |
| SCHEMBL5521929 | 0.84 | NFKB1 (0.42) | BLMTDP1ADRB2NFKB1KDM4E | |
| SCHEMBL7150478 | 0.77 | BLM (0.56) | BLMTDP1ADRB2NFKB1KDM4E | |
| SCHEMBL28530955 | 0.77 | AMY1A (0.45) | TDP1MAPTRECQLHPGDLMNA | |
| SCHEMBL25437216 | 0.76 | BACE1 (0.38) | — | |
| SCHEMBL15912526 | 0.76 | ALDH1A1 (0.40) | BLMTDP1KDM4EMAPTRECQL | |
| SCHEMBL5373425 | 0.76 | MEN1 (0.49) | BLMMAPTHPGDLMNAMAPK1 | |
| SCHEMBL15061878 | 0.75 | BLM (0.65) | BLMTDP1ADRB2NFKB1KDM4E | |
| SCHEMBL7152531 | 0.73 | ADRB2 (0.67) | BLMTDP1ADRB2NFKB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011081937-A1 | CORTICOSTEROID-BETA-AGONIST-MUSCARINIC ANTAGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | BLM 213/4885TDP1 3985/4885ADRB2 16/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | BLM 395/4885TDP1 4191/4885ADRB2 13/4885 |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | BLM 589/4885TDP1 2653/4885ADRB2 40/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | BLM 589/4885TDP1 2653/4885ADRB2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.